Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
14
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Imugene Ltd. market cap is $17.04M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Imugene Ltd. 52 week high is $0.295 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Imugene Ltd. 52 week low is $0.01 as of November 21, 2026.
Imugene Ltd. stock price today is $0.031.
Imugene Ltd. stock price yesterday was $0.029.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Imugene Ltd.'s P/E ratio is -0.14.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Imugene Ltd. P/B ratio is 2.0653.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Imugene Ltd. 50-day moving average is $0.0387.